Investigating how MG53 helps improve muscle function in ALS
Multifaceted role of MG53 in alleviating neuromuscular function decline in ALS
This study is looking at a protein called MG53 to see how it might help muscles heal better in people with ALS, a condition that causes muscle weakness, and could lead to new treatments to improve muscle and nerve function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-10875467 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called MG53 in the context of amyotrophic lateral sclerosis (ALS), a disease that leads to muscle weakness and respiratory failure. The study aims to explore how oxidative stress affects muscle repair and the neuromuscular junction, which is crucial for communication between nerves and muscles. By examining muscle tissue from ALS models, researchers will assess how MG53 can potentially enhance muscle membrane repair and overall neuromuscular function. Patients may benefit from insights that could lead to new therapeutic strategies for ALS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) who are experiencing muscle function decline.
Not a fit: Patients with other neuromuscular disorders or those in advanced stages of ALS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve muscle function and quality of life for ALS patients.
How similar studies have performed: Previous research has shown promising results in understanding muscle repair mechanisms in ALS, suggesting that this approach could yield valuable insights.
Where this research is happening
Arlington, United States
- University of Texas Arlington — Arlington, United States (Active)
Researchers
- Principal investigator: Zhou, Jingsong — University of Texas Arlington
- Study coordinator: Zhou, Jingsong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.